Adallen Pharma Limited
Adallen Pharma Limited, headquartered in Great Britain, is a prominent player in the pharmaceutical industry, specialising in the development and distribution of innovative healthcare solutions. Founded in 2015, the company has rapidly established itself in key operational regions across Europe and beyond, focusing on advanced drug formulations and delivery systems. With a commitment to quality and efficacy, Adallen Pharma offers a range of core products, including prescription medications and over-the-counter solutions that address various health conditions. Their unique approach to research and development has led to several notable achievements, positioning them as a trusted name in the market. As they continue to expand their portfolio, Adallen Pharma remains dedicated to improving patient outcomes through cutting-edge pharmaceutical advancements.
DitchCarbon Score
How does Adallen Pharma Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Adallen Pharma Limited's score of 16 is higher than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Adallen Pharma Limited's reported carbon emissions
In 2023, Adallen Pharma Limited reported total carbon emissions of approximately 59,000 kg CO2e, with emissions categorised into Scope 1, 2, and 3. Notably, Scope 1 emissions were recorded at 0 kg CO2e, indicating no direct emissions from owned or controlled sources. Scope 2 emissions, primarily from purchased electricity, accounted for about 5,000 kg CO2e. The majority of emissions stemmed from Scope 3, totalling approximately 54,000 kg CO2e, which includes significant contributions from purchased goods and services (20,000 kg CO2e), downstream transportation and distribution (14,000 kg CO2e), and employee commuting (1,000 kg CO2e). Despite the substantial emissions, Adallen Pharma Limited has not disclosed any specific reduction targets or initiatives aimed at mitigating their carbon footprint. The absence of formal climate commitments or reduction strategies suggests a need for further action in addressing their environmental impact. As the pharmaceutical industry increasingly prioritises sustainability, Adallen Pharma's future climate commitments will be crucial in aligning with global climate goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | |
|---|---|
| Scope 1 | - |
| Scope 2 | 5,000 |
| Scope 3 | 54,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Adallen Pharma Limited is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
